Entrada Non Currrent Assets Other vs Cash And Short Term Investments Analysis
| TRDA Stock | USD 18.80 0.75 4.16% |
Entrada Therapeutics financial indicator trend analysis is much more than just examining Entrada Therapeutics latest accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Entrada Therapeutics is a good investment. Please check the relationship between Entrada Therapeutics Non Currrent Assets Other and its Cash And Short Term Investments accounts. Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Entrada Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in unemployment. For information on how to trade Entrada Stock refer to our How to Trade Entrada Stock guide.
Non Currrent Assets Other vs Cash And Short Term Investments
Non Currrent Assets Other vs Cash And Short Term Investments Correlation Analysis
The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Entrada Therapeutics Non Currrent Assets Other account and Cash And Short Term Investments. At this time, the significance of the direction appears to have very strong relationship.
The correlation between Entrada Therapeutics' Non Currrent Assets Other and Cash And Short Term Investments is 0.8. Overlapping area represents the amount of variation of Non Currrent Assets Other that can explain the historical movement of Cash And Short Term Investments in the same time period over historical financial statements of Entrada Therapeutics, assuming nothing else is changed. The correlation between historical values of Entrada Therapeutics' Non Currrent Assets Other and Cash And Short Term Investments is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Non Currrent Assets Other of Entrada Therapeutics are associated (or correlated) with its Cash And Short Term Investments. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Cash And Short Term Investments has no effect on the direction of Non Currrent Assets Other i.e., Entrada Therapeutics' Non Currrent Assets Other and Cash And Short Term Investments go up and down completely randomly.
Correlation Coefficient | 0.8 |
| Relationship Direction | Positive |
| Relationship Strength | Strong |
Non Currrent Assets Other
Assets that are not physical or tangible, expected to provide value for more than one year, and not easily converted into cash, such as long-term investments or patents.Cash And Short Term Investments
Short Term Investments is an account in the current assets section of Entrada Therapeutics balance sheet. This account contains Entrada Therapeutics investments that will expire within one year. These investments include stocks and bonds that can be liquidated by Entrada Therapeutics fairly quickly. The sum of a company's cash on hand, including bank deposits and short-term, highly liquid investments that are easily convertible to known amounts of cash.Most indicators from Entrada Therapeutics' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Entrada Therapeutics current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Entrada Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in unemployment. For information on how to trade Entrada Stock refer to our How to Trade Entrada Stock guide.The current year's Enterprise Value is expected to grow to about 569.3 M, whereas Selling General Administrative is forecasted to decline to about 19.2 M.
| 2021 | 2023 | 2024 (projected) | Depreciation And Amortization | 1.1M | 2.8M | 3.0M | Interest Income | 2.6M | 15.2M | 16.0M |
Entrada Therapeutics fundamental ratios Correlations
Click cells to compare fundamentals
Entrada Therapeutics Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether Entrada Therapeutics offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Entrada Therapeutics' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Entrada Therapeutics Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Entrada Therapeutics Stock:Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Entrada Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in unemployment. For information on how to trade Entrada Stock refer to our How to Trade Entrada Stock guide.You can also try the Portfolio Backtesting module to avoid under-diversification and over-optimization by backtesting your portfolios.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Entrada Therapeutics. If investors know Entrada will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Entrada Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share 1.44 | Revenue Per Share 6.074 | Quarterly Revenue Growth (0.55) | Return On Assets 0.0695 | Return On Equity 0.1642 |
The market value of Entrada Therapeutics is measured differently than its book value, which is the value of Entrada that is recorded on the company's balance sheet. Investors also form their own opinion of Entrada Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Entrada Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Entrada Therapeutics' market value can be influenced by many factors that don't directly affect Entrada Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Entrada Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Entrada Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Entrada Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.